迈得医疗工业设备股份有限公司 投资者关系管理制度 第一章 总则 第二条 投资者关系管理是指上市公司通过便利股东权利行使、信息披露、 互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资 者对上市公司的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊 重投资者、回报投资者、保护投资者目的的相关活动。 第三条 公司通过充分的信息披露，并运用金融和市场营销的原理加强与投 资者之间的沟通，促进投资者对公司的了解和认同，实现公司价值最大化和股东 利益最大化。 第一条 为进一步完善迈得医疗工业设备股份有限公司（以下简称"公司"） 治理结构，规范公司投资者关系工作，加强公司与投资者和潜在投资者（以下统 称"投资者"）之间的沟通，促进公司完善治理，提高公司质量，切实保护投资者 特别是中小投资者合法权益，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上海证券交易所科创板股票上市规则》《上市公司投资者关系管理工 作指引》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规、规范性文件及《迈得医疗工业设备股份有限公司章程》（以 下简称"公司章程"）的规定，结合本公 ...

信息披露管理制度 第一章 总则 第一条 为规范迈得医疗工业设备股份有限公司（以下简称"公司"）及相关 义务人的信息披露工作，加强信息披露事务管理，保护投资者合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司信息披露管理办法》（以下简称"《管理办法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）等有关法律、法规、 规范性文件及《迈得医疗工业设备股份有限公司章程》（以下简称"公司章程"） 的规定，结合公司实际情况，制定本制度。 第二条 本制度中提及"信息"系指所有对公司股票及其衍生品种交易价格可 能产生较大影响的信息以及证券监管部门要求披露的信息；本制度中提及"披露" 系指在规定的时间在规定的媒体、以规定的方式向社会公众公布信息，并送达监 管部门备案。 第三条 本制度所称信息披露义务人是指： 迈得医疗工业设备股份有限公司 （一）公司董事和董事会； 第二章 信息披露的宗旨 第八条 公司及相关信息披露义务人应当同时向所有投资者公开披露重大信 息，确保所有投资者可以平等地获取同一信息，不得私下提前向特定对象单独披 露、透露或者泄露。但是，法 ...

Core Insights - Hangzhou has achieved the top position in the "2025 China Private Enterprises 500 Strong" rankings across five categories, including manufacturing, services, R&D investment, and invention patents [1][3]. Group 1: Rankings Overview - Hangzhou leads the nation in the number of companies listed in the "2025 China Private Enterprises 500 Strong" across all five categories [1]. - The threshold for inclusion in the "2025 Private Enterprises R&D Investment 500" list was set at 465 million yuan, with 36 companies from Hangzhou making the list, representing 7.20% of the national total and 37.89% of Zhejiang province [1][3]. - For the "2025 Private Enterprises Invention Patents 500" list, the entry requirement was 187 patents, with 42 companies from Hangzhou included, accounting for 8.40% of the national total and 36.52% of Zhejiang province [1][3]. Group 2: Notable Companies - Key companies from Hangzhou that made it to the "2025 Private Enterprises R&D Investment 500" list include Alibaba (China) Co., Ltd., Zhejiang Geely Holding Group Co., Ltd., and Ant Technology Group Co., Ltd. [3][4]. - The "2025 Private Enterprises Invention Patents 500" list features companies such as Alibaba (China) Co., Ltd., Ant Technology Group Co., Ltd., and Zhejiang Dahua Technology Co., Ltd. [7][9].

Core Viewpoint - Midea Medical has shown significant stock performance with an 85.93% increase year-to-date, indicating strong market interest and potential growth in the medical equipment sector [1][2]. Financial Performance - As of June 30, 2025, Midea Medical reported a revenue of 141 million yuan, a year-on-year decrease of 14.75%, and a net profit of 6.0451 million yuan, down 38.81% compared to the previous year [2]. - The company has distributed a total of 202 million yuan in dividends since its A-share listing, with 99.2975 million yuan distributed over the last three years [3]. Stock Market Activity - Midea Medical's stock price reached 20.08 yuan per share, with a trading volume of 26.1797 million yuan and a turnover rate of 0.80% [1]. - The stock has experienced a net inflow of 608,600 yuan from major funds, with significant buying activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.80% to 3,805, while the average number of circulating shares per person increased by 5.05% to 43,684 shares [2]. - Notable shareholders include 华夏行业景气混合A and 华夏远见成长一年持有混合A, with the former maintaining its position and the latter being a new entrant among the top shareholders [3]. Business Overview - Midea Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1]. - The company's main revenue sources include safety infusion connection machines (42.18%), blood purification connection machines (37.90%), and safety infusion single machines (14.04%) [1].

Core Viewpoint - Midea Medical's stock rose by 5.79% on September 16, reaching 20.66 yuan per share, with a total market capitalization of 3.434 billion yuan [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019. The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main business revenue composition includes: 42.18% from safe infusion line machines, 37.90% from blood purification line machines, 14.04% from safe infusion single machines, and 5.87% from other categories [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under Guotai Fund holds a significant position in Midea Medical. The Guotai Value Flexible Allocation Mixed Fund (005746) held 200,000 shares in the second quarter, accounting for 1.08% of the fund's net value, ranking as the eighth largest heavy stock [2] - The fund has generated an estimated floating profit of approximately 226,000 yuan today [2] Fund Performance - The Guotai Value Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 273 million yuan. Year-to-date returns are 5.47%, ranking 6623 out of 8174 in its category; the one-year return is 10.46%, ranking 6881 out of 7982; and since inception, the return is 46.99% [2] Fund Managers - The fund managers are Cheng Zhou and Cheng Yao. Cheng Zhou has a cumulative tenure of 17 years and 171 days, with a total fund asset scale of 6.594 billion yuan, achieving a best fund return of 361.33% and a worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 71 days, managing a total fund asset scale of 1.921 billion yuan, with a best fund return of 14.74% and a worst return of 3.78% during her tenure [3]

Core Viewpoint - The company is focusing on integrating its contact lens business with CDMO and proprietary brand sales, aiming to develop a multi-brand matrix to capture customer segments. Group 1: Financial Performance - As of June 30, 2025, the company's contract liabilities amounted to 181.57 million yuan, an increase of 83.28% compared to the end of the previous year, indicating a growth in orders that supports the recovery of the main business [2][3]. - The current market capitalization of the company is 3.26 billion yuan, ranking 68th out of 78 in the automation equipment sector and 4346th out of 5153 in the A-share market [1]. Group 2: Product Development - The company is applying for registration of daily disposable soft contact lenses, while the silicone hydrogel products are still in the research and sample preparation stage [2][3]. - The company plans to start with the hydrogel series for its contact lens products and will subsequently develop silicone hydrogel series and functional soft lenses [1]. Group 3: Market Dynamics - The safety infusion equipment segment is currently under pressure due to reduced investment willingness from downstream customers and intensified domestic competition [1][3]. - The blood purification equipment segment is maintaining a growth trend, benefiting from the ongoing domestic replacement of blood dialysis devices [1][3]. - New product categories, including pre-filled series devices and insulin injection pen series devices, are showing positive trends due to the development of biopharmaceuticals, medical aesthetics, and weight-loss drug markets [1].

Core Insights - The company is optimistic about the future of its contact lens business, particularly with the launch of monthly disposable colored contact lenses and plans for further development in this area [1][2] Group 1: Business Development - The company will continue to focus on research and development of materials, product certification, launching its own brand, new product development, and optimizing production lines to reduce costs [1] - There is an emphasis on integrating the upstream and downstream supply chain of the contact lens industry [1] - The company plans to enhance talent acquisition in areas such as materials, optics, design, and sales to develop products that meet market demands [1] Group 2: Competitive Advantage - The company differentiates itself from mainstream colored contact lens brands by positioning its contact lens business as integrated production and sales [1] - The production lines for contact lenses are developed and manufactured in-house, leveraging over 20 years of equipment manufacturing expertise [1] - The company can quickly optimize and improve equipment based on production line adjustments and market feedback, which helps in cost optimization [1] Group 3: Product Development - The company is currently applying for registration certificates for daily disposable soft hydrophilic contact lenses [2] - The silicone hydrogel product is still in the research and sample preparation stage [2]

Group 1 - The core point of the article is that Maider Medical (688310) has seen a significant increase in its stock price, closing at 21.17 yuan, which is a 7.63% rise from the previous week [1] - The stock reached a nearly one-year high of 21.38 yuan during intraday trading on September 5, 2025, with a low of 19.43 yuan on September 3, 2025 [1] - The current total market capitalization of Maider Medical is 3.519 billion yuan, ranking 65th out of 78 in the automation equipment sector and 4141st out of 5152 in the A-share market [1] Group 2 - Maider Medical will hold a semi-annual performance briefing on September 10, 2025, where investors can submit questions in advance [1] - The briefing will be conducted via the Shanghai Stock Exchange Roadshow Center, featuring key company personnel including the Chairman and General Manager Lin Junhua, Secretary of the Board Lin Dong, and Financial Officer Lin Junhui [1] - Investors can participate online and submit questions during the event, with the opportunity to review the meeting afterward on the same platform [1]

Core Insights - The total margin balance of the STAR Market on September 3 was 228.939 billion yuan, a decrease of 1.9 billion yuan from the previous trading day [1] - The financing balance was 228.159 billion yuan, down by 1.892 billion yuan, while the securities lending balance was 0.78 billion yuan, a decrease of 0.08 billion yuan [1] Individual Stock Performance - On September 3, 258 stocks in the STAR Market experienced net financing inflows, with 10 stocks having net inflows exceeding 30 million yuan [1] - Dongxin Technology topped the list with a net financing inflow of 263 million yuan, followed by Baiji Shenzhou, Airo Energy, Yuanjie Technology, and Shijia Photon, all with net inflows exceeding 50 million yuan [1]

Summary of Key Points - On September 3, a total of 33 stocks were identified with institutional activity, with 15 stocks showing net buying and 18 stocks showing net selling [1] - The top three stocks with the highest net buying by institutions were Chenxin Pharmaceutical, Xiaocheng Technology, and Airo Energy, with net buying amounts of 116 million, 111 million, and 72.55 million respectively [1] - The top three stocks with the highest net selling by institutions were Yuanjie Technology, Chengdu Huamei, and Julun Intelligent, with net outflow amounts of 409 million, 112 million, and 98.8 million respectively [1]